SPRAY DOSAGE FORMS: A PROMISING APPROACH TO SYSTEMIC PHARMACOTHERAPY
DOI:
https://doi.org/10.22159/ijap.2025v17i3.53398Keywords:
Nasal sprays, Oral sprays, Dosage formAbstract
This article discusses the development of spray medications as a novel and promising approach in therapy, focusing on their advantages, disadvantages, and potential applications. The main idea highlights the importance of innovative drug delivery systems, such as spray formulations, in modern medicine. The article reviews various studies and evaluates the effectiveness of sprays in systemic therapy, emphasizing their benefits in terms of rapid drug action, reduced side effects, patient compliance, dosing accuracy, and convenience of use. This method has several significant advantages: a fast onset of action; for example, nitroglycerin absorption under the tongue occurs very quickly, with maximum plasma concentration reached within 5–8 min, reduced side effects, and increased patient adherence to treatment. Furthermore, the article explores the different types of sprays, including dosing, nasal, and oral sprays, and their applications in cardiovascular diseases, hypertension, headache, insomnia, and erectile dysfunction. The potential for future innovations in spray technology, such as nanotechnology for enhanced drug delivery, controlled release formulations, and specialized formulations for specific conditions, is also discussed. In conclusion, the article points out the promising prospects for the development of spray medications to optimize therapeutic approaches and improve patient outcomes in a wide range of diseases.
References
Okladnikov SM, Nikitina SY, Aleksandrova GA, Akhmetzyanova RR, Golubev NA, Kirillova GN Chumarina VZh. editors. In: Healthcare in Russia. 1st ed. Moscow: Federal State Statistics Service: Statistical Collection; 2023.
Sprays (OFS.1.4.1.0046). State Pharmacopoeia of the Russian Federation, 15th Editor, Part 1. Moscow; 2007. pp. 624–27.
Landau AJ, Eberhardt RT, Frishman WH. Intranasal delivery of cardiovascular agents: an innovative approach to cardiovascular pharmacotherapy. Am Heart J. 1994 Jun;127(6):1594-9. doi: 10.1016/0002-8703(94)90391-3, PMID 8197988.
Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007 Jun 7;337(1-2):1-24. doi: 10.1016/j.ijpharm.2007.03.025, PMID 17475423.
Huston J, Genovese A, Ashchi A, DeLuca A, Wiener J, Deeb E. Correction to: Etripamil nasal spray: therapeutic potential for treating paroxysmal supraventricular tachycardia. Am J Cardiovasc Drugs Am J Cardiovasc Drugs. 2023;23(6):735-6. doi: 10.1007/s40256-023-00595-4, PMID 37477826.
Hassan RH, Gad HA, Shaker DS, Ishak RA. Exploring the potential of intranasal drug delivery systems in the management of hypertension. RPS Pharmacy and Pharmacology Reports. 2023;2(2):1-18. doi: 10.1093/rpsppr/rqad021.
Stambler BS, Plat F, Sager PT, Shardonofsky S, Wight D, Potvin D. First randomized multicenter placebo controlled study of self administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022 Dec;15(12):e010915. doi: 10.1161/CIRCEP.122.010915, PMID 36441560, PMCID PMC9760458.
Fortuna A, Alves G, Serralheiro A, Sousa J, Falcao A. Intranasal delivery of systemic acting drugs: small molecules and biomacromolecules. Eur J Pharm Biopharm. 2014 Sep;88(1):8-27. doi: 10.1016/j.ejpb.2014.03.004, PMID 24681294.
Tai J, Han M, Lee D, Park IH, Lee SH, Kim TH. Different methods and formulations of drugs and vaccines for nasal administration. Pharmaceutics. 2022 May 17;14(5):1073. doi: 10.3390/pharmaceutics14051073, PMID 35631663, PMCID PMC9144811.
Tucker C, Tucker L, Brown K. The intranasal route as an alternative method of medication administration. Crit Care Nurse. 2018 Oct;38(5):26-31. doi: 10.4037/ccn2018836, PMID 30275061.
Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022 Apr;12(4):735-57. doi: 10.1007/s13346-020-00891-5, PMID 33491126, PMCID PMC7829061.
Abuelazm M, Kambalapalli S, Saleh O, Elzeftawy MA, Albakri K, Gowaily I. The efficacy and safety of etripamil nasal spray for acute paroxysmal supraventricular tachycardia: a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2023 Jul;23(4):379-91. doi: 10.1007/s40256-023-00592-7, PMID 37351813, PMCID PMC10328856.
Varounis C, Katsi V, Nihoyannopoulos P, Lekakis J, Tousoulis D. Cardiovascular hypertensive crisis: recent evidence and review of the literature. Front Cardiovasc Med. 2017 Jan;3:51. doi: 10.3389/fcvm.2016.00051, PMID 28119918, PMCID PMC5222786.
Tulman DB, Stawicki SP, Papadimos TJ, Murphy CV, Bergese SD. Advances in management of acute hypertension: a concise review. Discov Med. 2012 May;13(72):375-83. PMID 22642919, PMCID PMC3727280.
Stewart MH. Hypertensive crisis: diagnosis presentation and treatment presentation. Curr Opin Cardiol. 2023 Jul 1;38(4):311-7. doi: 10.1097/HCO.0000000000001049, PMID 37016936.
Watson K, Broscious R, Devabhakthuni S, Noel ZR. Focused update on pharmacologic management of hypertensive emergencies. Curr Hypertens Rep. 2018 Jun 8;20(7):56. doi: 10.1007/s11906-018-0854-2, PMID 29884955.
Kubota R, Komiyama T, Shimada H. Evaluation of the method for nifedipine administration for a rapid onset of clinical effect: a clinical study in normal volunteers. Yakugaku Zasshi. 2001 May;121(5):355-64. doi: 10.1248/yakushi.121.355, PMID 11360489.
Kinoshita R, Ishida K, Sendaya K, Miyagawa A, Oda S, Taniguchi K. Clinical evaluation of isosorbide dinitrate (ISDN) spray: a study on the plasma concentrations of ISDN and on its hemodynamic effects using three administration routes. Masui. 1990 Dec;39(12):1660-3. PMID 2098594.
Hafner A. Advances in development, characterisation and application of nasal drug delivery systems. Pharmaceutics. 2022 Jul 27;14(8):1562. doi: 10.3390/pharmaceutics14081562, PMID 36015187, PMCID PMC9415911.
Kulkarni S, Glover M, Kapil V, Abrams SM, Partridge S, MC Cormack T. Management of hypertensive crisis: british and irish hypertension society position document. J Hum Hypertens. 2023 Oct;37(10):863-79. doi: 10.1038/s41371-022-00776-9, PMID 36418425, PMCID PMC10539169.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. Seventh report of the joint national committee on prevention detection evaluation and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2, PMID 14656957.
Kar S, Das SS, Kundu S, Sahu BD, Kumar KJ, Kesari KK. Intranasal delivery of carvedilol and quercetin encapsulated cationic nanoliposomes for cardiovascular targeting: formulation and in vitro and ex vivo studies. ACS Appl Bio Mater. 2024 May 20;7(5):3061-85. doi: 10.1021/acsabm.4c00102, PMID 38581388, PMCID PMC11530090.
Jagdale S, Shewale N, Kuchekar BS. Optimization of thermoreversible in situ nasal gel of timolol maleate. Scientifica (Cairo). 2016;2016:6401267. doi: 10.1155/2016/6401267, PMID 27293975, PMCID PMC4884840.
Dandagi PM, Mastiholimath VS, Gadad AP, Iliger S. Mucoadhesive microspheres of propranolol hydrochloride for nasal delivery. Indian J Pharm Sci. 2007;69(3). doi: 10.4103/0250-474X.34550.
Alabsi W, Eedara BB, Encinas Basurto D, Polt R, Mansour HM. Nose to brain delivery of therapeutic peptides as nasal aerosols. Pharmaceutics. 2022 Sep 5;14(9):1870. doi: 10.3390/pharmaceutics14091870, PMID 36145618, PMCID PMC9502087.
Calvert P, Gupta D. Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia. Future Cardiol. 2024;20(3):163-70. doi: 10.1080/14796678.2024.2342651, PMID 38717391, PMCID PMC11216497.
Raja JM, Cave B, Jefferies JL, Khouzam RN. Etripamil: intranasal calcium channel blocker: a novel noninvasive modality in the treatment of paroxysmal supraventricular tachycardia. Curr Probl Cardiol. 2021 Mar;46(3):100430. doi: 10.1016/j.cpcardiol.2019.05.003, PMID 31279494.
Faisaluddin M, Ashish K, Hajra A, Mondal S, Bandyopadhyay D. Etripamil: self-management of supraventricular tachycardia is not far away? Int J Cardiol Heart Vasc. 2019 Jan 4;22:82-3. doi: 10.1016/j.ijcha.2018.12.007, PMID 30627628, PMCID PMC6321861.
Zaharia Czeizler V. Erythropoietin stops chronic diffuse transfusion-dependent gastrointestinal bleeding. Ann Intern MedAnn Intern Med. 2001;135(10):933. doi: 10.7326/0003-4819-135-10-200111200-00028, PMID 11712898.
Kagedal M, Zingmark PH, Hedlund C, Yates R. True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers. Am J Drug Deliv. 2005;3(2):133-40. doi: 10.2165/00137696-200503020-00005.
Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised double blind placebo controlled dose ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17(9):653-67. doi: 10.2165/00023210-200317090-00005, PMID 12828501.
Amelin AV, Vaganova IS, Koreshkina MI, Tereshchenko NM. Efficacy of zolmitriptan nasal spray in adult patients with migraine. Medicinskij sovet. 2023;(13):65-71. doi: 10.21518/ms2023-259.
Antonaci F, Chimento P, Diener HC, Sances G, Bono G. Lessons from placebo effects in migraine treatment. J Headache Pain. 2007 Feb;8(1):63-6. doi: 10.1007/s10194-007-0360-4, PMID 17361384.
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults overview of cochrane reviews. Cochrane Database Syst Rev. 2014;2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2, PMID 24865446.
Antonaci F, Ghiotto N, WU S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016 May 17;5:637. doi: 10.1186/s40064-016-2211-8, PMID 27330903.
Porter SC. Novel drug delivery: review of recent trends with oral solid dosage forms. Am Pharm Rev. 2001;4:28-36.
Connell AO, Malley DO, Wilson C, Katz D, Sahar M, Martin M. Microinfusion of sumatriptan from medipad a novel delivery system. ProcInt Symp Control Relbioact Mater. 1997;24:981-2.
Tsals I, Gross Y, Rozanowich M, Katz D, Sahar M. Back pressure during subcutaneous infusion by medipad drug delivery system. Proc Int Symp Control Relbioact Mater. 1999;26:1060-1.
Mohamed Jasim PP, Thasneem CK, Shiji Kumar PS, Sirajudheen MK. Novel insulin delivery methods for diabetes mellitus. Int J Mod Pharm Res. 2020;4(3):97-104.
Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001;40(9):661-84. doi: 10.2165/00003088-200140090-00003, PMID 11605715.
Neubauer DN. Zolpi Mist™: a new formulation of zolpidem tartrate for the short term treatment of insomnia in the US. Nat Sci Sleep. 2010 May 10;2:79-84. doi: 10.2147/nss.s6431, PMID 23616700.
Kamalov АА, Ohobotov DA, Kadrev AV. Sildenafil citrate in the form of a spray and tablet: initial results of a single center comparative study. Urology. 2022;3:63-70.
Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, AkhoundiKharanaghi E, Mohammadnejad Arough J. Overview of preparation methods of polymeric and lipid based (niosome solid lipid liposome) nanoparticles: a comprehensive review. Int J Polym Mater Polym Biomater. 2018 Apr;67(6):383–400.
Wilson DR, Sen R, Sunshine JC, Pardoll DM, Green JJ, Kim YJ. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine. 2018 Feb;14(2):237-46. doi: 10.1016/j.nano.2017.10.013, PMID 29127039.
Rizvi SA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018 Jan;26(1):64-70. doi: 10.1016/j.jsps.2017.10.012, PMID 29379334.
Elbardisy B, Boraie N, Galal S. Tadalafil nanoemulsion mists for treatment of pediatric pulmonary hypertension via nebulization. Pharmaceutics. 2022 Dec 5;14(12):2717. doi: 10.3390/pharmaceutics14122717, PMID 36559211.
Pratiwi l, Sari R, Apridamayanti P. Design and characterization of nanospray with self-nanoemulsifying drug delivery system using sinergistic combination of melastoma malabathricum l. Fraction and gentamicin. Int J Appl Pharm. 2021 Mar;13(2):254-63.
James J, Rani J, Varadarajan S. Nano carrier drug delivery systems for the treatment of cognitive dysfunction in depression an overview on the nano formulations targeting to the brain. Int J Appl Pharm. 2022 Jul;14:28-33.
Published
How to Cite
Issue
Section
Copyright (c) 2025 LUKOYANOVA S. A., SENTURIN MICHAIL A., SOLOVIEVA N. L., IVAN IVANOVICH, KOZLOVA ZHANNA M.
This work is licensed under a Creative Commons Attribution 4.0 International License.
